Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-16-005806
Filing Date
2016-05-10
Accepted
2016-05-10 16:03:24
Documents
52
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q adms-20160331x10q.htm 10-Q 1288858
2 EX-10.1 adms-20160331ex101506eb1.htm EX-10.1 33947
3 EX-10.2 adms-20160331ex1025834f0.htm EX-10.2 44078
4 EX-31.1 adms-20160331ex311d9ee84.htm EX-31.1 12207
5 EX-31.2 adms-20160331ex312d30a81.htm EX-31.2 12245
6 EX-32.1 adms-20160331ex32192c796.htm EX-32.1 11911
7 GRAPHIC adms20160331ex101506eb1001.jpg GRAPHIC 5770
8 GRAPHIC adms20160331ex1025834f0001.jpg GRAPHIC 2885
  Complete submission text file 0001558370-16-005806.txt   4581293

Data Files

Seq Description Document Type Size
9 EX-101.INS adms-20160331.xml EX-101.INS 868540
10 EX-101.SCH adms-20160331.xsd EX-101.SCH 30141
11 EX-101.CAL adms-20160331_cal.xml EX-101.CAL 33143
12 EX-101.DEF adms-20160331_def.xml EX-101.DEF 114242
13 EX-101.LAB adms-20160331_lab.xml EX-101.LAB 331937
14 EX-101.PRE adms-20160331_pre.xml EX-101.PRE 221317
Mailing Address 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608
Business Address 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608 510-450-3554
Adamas Pharmaceuticals Inc (Filer) CIK: 0001328143 (see all company filings)

EIN.: 421560076 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36399 | Film No.: 161635688
SIC: 2834 Pharmaceutical Preparations